CFDA approved sanofitasotide (docetaxel injection) for the first-line treatment of advanced gastric cancer

This scheme, which is composed of docetaxel combined with cisplatin and 5-fluorouracil (DCF scheme), is used to treat advanced gastric adenocarcinoma, including adenocarcinoma at the junction of stomach and esophagus, which has not received chemotherapy before It provides a new choice of chemotherapy scheme based on evidence-based medicine and more suitable for Chinese patients with gastric cancer After breast cancer, lung cancer and prostate cancer, this is the fourth indication approved by docetaxel (docetaxel injection) in China Professor Ji Jiafu, Dean of Cancer Hospital Affiliated to Peking University, said, "about 40% of gastric cancer patients in China are in advanced stage when they are diagnosed, and their five-year survival rate is less than 10% They urgently need more effective drugs and treatment programs to prolong their lives "The v325 study is the first to confirm that the addition of docetaxel (DCF) to cisplatin combined with 5-FU chemotherapy regimen can significantly prolong the survival time and improve the remission rate of untreated patients with metastatic or recurrent gastric cancer However, while v325 achieved good results, there was also a high incidence of adverse reactions Therefore, at the beginning of the design of Taxotere ® China advanced gastric cancer registration study, based on the existing clinical experience and full consideration of the tolerance of Chinese patients, the dosage of chemotherapy drugs was adjusted The results showed that compared with cisplatin combined with 5-FU chemotherapy, the dose adjusted DCF regimen significantly improved the overall remission rate (ORR) (48.7% vs 33.9%) and prolonged the progression free survival (PFS) (7.2 months vs 4.9 months) and overall survival (OS) (10.2 months vs 8.5 months) of patients with metastatic or recurrent gastric cancer who had not received chemotherapy before Professor Shen Lin, vice president of Peking University Cancer Hospital, said: "the results of this study show that the DCF chemotherapy regimen after dose adjustment has the same efficacy as the foreign regimen, and the incidence of adverse reactions is relatively lower Therefore, the safety and quality of life of patients are improved to the greatest extent while ensuring the curative effect "According to the latest epidemiological data, gastric cancer is the second most common cancer in China More than 40% of the global gastric cancer patients come from China In the past five years, 400000 new cases of gastric cancer occur in China every year, which brings great pain to patients and their families Mr long Xianli, senior vice president of Sanofi Asia and President of China, said: "the approval of the first-line treatment indications of Taxotere ® advanced gastric cancer practically provides Chinese clinicians with a new choice of chemotherapy with definite curative effect, so as to meet the treatment needs of patients to prolong their survival, alleviate their symptoms and improve their quality of life Sanofi has been working with global and Chinese clinical institutions to provide the best treatment drugs and programs for Chinese patients "(Bio Valley bio Com) about Sanofi Sanofi is a leading diversified medical and health enterprise in the world, focusing on the needs of patients, researching, developing and promoting innovative treatment solutions Sanofi has core advantages in seven growth platforms: integrated management of diabetes, human vaccines, innovative drugs, health pharmaceutical industry, emerging markets, animal health care and rare diseases (jianzan) Sanofi is listed in Paris (European stock exchange code: San) and New York (New York Stock Exchange code: sNY) For more information, visit www.sanofi.com 2014 marks the 50th anniversary of the establishment of diplomatic relations between the French Republic and the people's Republic of China As one of the major sponsors of the celebration, Sanofi will support and participate in a number of science and technology activities in France and China, and reaffirm its commitment to the development of China's economy and public health care About Sanofi China Sanofi entered China in the early 1980s, headquartered in Shanghai, its business covers prescription drugs, vaccines, health medicine, rare diseases (jianzan) and animal health (meiria) The group has 11 regional offices in Beijing, Tianjin, Shenyang, Jinan, Shanghai, Hangzhou, Nanjing, Wuhan, Chengdu, Guangzhou and Urumqi, and 7 production bases in Beijing, Hangzhou, Nanchang, Tangshan, Shenzhen and Nanjing By the end of 2013, Sanofi had nearly 8500 employees in China Sanofi has China R & D center and Asia Pacific R & D center in Shanghai, and R & D teams in Beijing and Chengdu, with the overall R & D strength from drug target discovery to later clinical research For more information, please visit www.sanofi.cn.